Numbing cream may ease sting of cancer mapping shots
NCT ID NCT06223659
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tests whether EMLA numbing cream can reduce pain from Technetium 99 injections used in lymphoscintigraphy, a standard mapping procedure for skin cancers like melanoma. About 100 adults with skin cancer will receive either EMLA cream or a placebo before the injection. The goal is to see if the cream makes the procedure less painful.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for CUTANEOUS MELANOMA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Email: •••••@•••••
Locations
-
Ohio State University Comprehensive Cancer Center
RECRUITINGColumbus, Ohio, 43210, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- E-Learning could sharpen Doctors' eye for skin cancer
- Can Pre-Surgery immunotherapy prime the immune system to fight head and neck cancer?
- Can a new drug tame advanced solid tumors?
- Can a short Pre-Surgery immunotherapy course replace Long-Term adjuvant treatment for melanoma?
- Glowing cancer cells: a new way to see tumors during surgery?
- Can a single tracer light up cancer's first stop? a trial puts a hybrid dye-and-radioactive marker to the test.